ArticleInternational journal of clinical oncology2010
Clinicopathological features and treatment strategy for triple-negative breast cancer.
Article in International journal of clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Deep learning analysis of contrast-enhanced spectral mammography to determine histoprognostic factors of malignant breast tumours.European radiology · 2022Article
- Comparison of ultrasonographic and mammographic features of extremely rare papillary carcinoma and invasive ductal carcinoma.Contemporary oncology (Poznan, Poland) · 2022Article
- Correlation of dynamic contrast-enhanced MRI and diffusion-weighted MR imaging with prognostic factors and subtypes of breast cancers.Frontiers in oncology · 2022Article
- Anticancer potential of (-)-epicatechin in a triple-negative mammary gland model.The Journal of pharmacy and pharmacology · 2021Article
- Comparison of clinical and magnetic resonance imaging findings of triple-negative breast cancer with non-triple-negative tumours.Polish journal of radiology · 2021Article
- Delayed initiation of adjuvant chemotherapy in older women with breast cancer.Cancer medicine · 2020Observational
- Clinicopathological, Treatment and Event-Free Survival Characteristics in a Moroccan Population of Triple-Negative Breast Cancer.Breast cancer : basic and clinical research · 2020Article
- Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?Breast cancer research and treatment · 2019Article
- The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer.Journal of Cancer · 2018Article
- A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of UnknownClinical Medicine Insights. Oncology · 2018Article
- 15α-methoxypuupehenol Induces Antitumor EffectsMolecular cancer therapeutics · 2017Article
- Article
- Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial.Contemporary oncology (Poznan, Poland) · 2017Article
- Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature.OncoTargets and therapy · 2017Article
- Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors.Iranian journal of radiology : a quarterly journal published by the Iranian Radiological Society · 2016Article
- Molecular characteristics of recurrent triple-negative breast cancer.Molecular medicine reports · 2015Article
- High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.Molecular oncology · 2015Article
- Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancers are divided into at least 4 subtypes on the basis of gene expression profiles and expression of receptors (hormone receptors (HR) and HER2) as measured by immunohistochemistry. These subtypes have different prognoses and responses to treatments such as endocrine manipulation, anti-HER2 therapy, and chemotherapy. Triple-negative breast cancer (TNBC) is immunohistochemically defined as lacking estrogen and progesterone receptors and not overexpressing HER2. TNBC accounts for approximately 15% of breast cancer patients, and is more chemosensitive but has a worse prognosis than the HR-positive/HER2-negative phenotype. TNBC is a heterogeneous disease that does not offer specific targets in the same way as HR-positive and HER2-positive breast cancers, and is similar to basal-like breast cancer and BRCA1-related breast cancer. At present, the lack of highly effective therapeutic targets for TNBC leaves standard chemotherapy, for example the combination of anthracycline and taxane, as the only medical treatment, but this is insufficiently efficacious. Novel approaches for TNBC, for example DNA damaging agents, PARP-1 inhibitors, receptor tyrosin kinase inhibitors (TKIs), and antiangiogenesis agents, have been examined in clinical settings. Concerning therapeutic strategies for TNBC, it is most important to develop novel effective approaches for TNBC treatment and high-throughput predictive tools for standard chemotherapy and novel agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.